SK pharmteco partners with Prozomix to expand biocatalysis in drug manufacturing. Discover what this means for greener APIs and global CDMO strategy.
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Explore trial design, dosing strategy, and risks.
Avalyn Pharma advances inhaled AP02 into Phase 2 trials for IPF. Learn how lung targeted delivery could reshape antifibrotic treatment.
Can HMPL-760 improve outcomes in relapsed DLBCL? Explore how HUTCHMED is advancing next-gen BTK inhibitors in China.
IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.
Apogee Therapeutics prepares to release 52-week APEX data for zumilokibart. Discover what it could mean for eczema treatment and competition.
Discover how Alamar Biosciences’ Neuro 220 Panel could transform CNS biomarker research and accelerate diagnostics and trials.
Myriad Genetics secures FDA approval for MyChoice CDx in ovarian cancer. Discover how HRD testing could reshape PARP inhibitor treatment decisions.
Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.
FDA approves Novartis Cosentyx for adolescent hidradenitis suppurativa. Discover what this decision means for biologic treatment strategies.